Get the Stockscreener App
20.84
4.36%
0.87
Castle Biosciences Inc stock is traded at $20.84, with a volume of 354.98K.
It is up +4.36% in the last 24 hours and up +27.70% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$19.97
Open:
$20.13
24h Volume:
354.98K
Relative Volume:
0.73
Market Cap:
$604.53M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-9.693
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+3.73%
1M Performance:
+27.70%
6M Performance:
-19.07%
1Y Performance:
-24.30%
1-Day Range:
$20.00
$21.03
1-Week Range:
$19.23
$21.03
52-Week Range:
$14.59
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
20.84 | 596.41M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Is Castle Biosciences Inc.’s ROE strong enoughWeekly Gains Report & Free Weekly Watchlist of Top Performers - newsyoung.net
Published on: 2025-08-16 21:19:23 - sundaytimes.kr
Why Castle Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Retail & Target Return Focused Stock Picks - mustnews.co.kr
Predictive Oncology Q2 EPS 22c, down from 53c YoY, revenue at $2,682, down from $67,255 YoY. - AInvest
Is Castle Biosciences Inc. in a consolidation phaseMarket Sentiment Summary & Free Reliable Trade Execution Plans - thegnnews.com
What is the PEG ratio of Castle Biosciences Inc.2025 Price Action Summary & Growth Focused Investment Plans - classian.co.kr
Will Castle Biosciences Inc. outperform tech stocksMax Yield Daily Selections - mustnews.co.kr
Castle Biosciences Updates Bylaws for Improved Governance - TipRanks
CSTL SEC FilingsCastle Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Price Clustering Detected in Castle Biosciences Inc. StockExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Castle Biosciences (CSTL) and Regeneron (REGN) - The Globe and Mail
Castle Biosciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Castle Biosciences Reports Strong Q2 2025 Results - TipRanks
Barrett Business Reports Q2 GAAP EPS of $0.70, Beating Estimates by $0.01 - AInvest
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences Maintains Strong Buy Rating with $32 Price Target - AInvest
Castle Biosciences Raises Revenue Guidance Amid Growth and Challenges - AInvest
Robert W. Baird Sticks to Its Buy Rating for Castle Biosciences (CSTL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie, Castle Biosciences, and Regeneron - AInvest
Castle Biosciences’ Earnings Call: Growth Amid Challenges - TipRanks
Castle Biosciences Outpaces Expectations With Bright Forecast - Finimize
Castle Biosciences Outpaces Estimates And Ups Forecast - Finimize
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - MSN
Castle Biosciences Reports Strong Q2 2025 Financial Results - MSN
Castle Biosciences Soars 22.52% on Strong Q2 Earnings - AInvest
Castle Biosciences Q2 2025 Earnings Call Highlights: Strong Revenue Growth Despite Challenges - AInvest
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Castle Biosciences Reports Second Quarter 2025 Results - The Manila Times
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Castle Biosciences Q2 2025 Earnings Exceed Expectations with $86.2M Revenue, $0.16 EPS, and Strong Gross Margin of 77% - AInvest
Castle Biosciences: A Strategic Bet on Personalized Oncology Diagnostics - AInvest
Transcript : Castle Biosciences, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com
Medical testing provider Castle Bio raises annual revenue guidance - MarketScreener
Castle Biosciences Q2 2025 slides: Test volume surges 33% amid declining margins - Investing.com India
Shareholders in Castle Biosciences (NASDAQ:CSTL) have lost 65%, as stock drops 10% this past week - simplywall.st
What drives Castle Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the dividend policy of Castle Biosciences Inc. stockHigh-octane gains - Jammu Links News
What are analysts’ price targets for Castle Biosciences Inc. in the next 12 monthsMaximize portfolio returns with smart trading - Jammu Links News
What catalysts could drive Castle Biosciences Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
What are Castle Biosciences Inc. company’s key revenue driversOutstanding growth strategies - Jammu Links News
Should I hold or sell Castle Biosciences Inc. stock in 2025Phenomenal capital gains - Jammu Links News
What institutional investors are buying Castle Biosciences Inc. stockMaximize your portfolio’s earning potential - Jammu Links News
When is Castle Biosciences Inc. stock expected to show significant growthRapid portfolio appreciation - Jammu Links News
How volatile is Castle Biosciences Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
How many analysts rate Castle Biosciences Inc. as a “Buy”Free Stock Selection - Jammu Links News
Castle Biosciences Q2 Earnings Preview: Analysts Expect $-0.50 EPS - AInvest
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):